| Literature DB >> 33803588 |
Mirjana Mihailović1, Svetlana Dinić1, Jelena Arambašić Jovanović1, Aleksandra Uskoković1, Nevena Grdović1, Melita Vidaković1.
Abstract
Diabetes is a complex metabolic disorder resulting either from insulin resistance or an impaired insulin secretion. Prolonged elevated blood glucose concentration, the key clinical sign of diabetes, initiates an enhancement of reactive oxygen species derived from glucose autoxidation and glycosylation of proteins. Consequently, chronic oxidative stress overwhelms cellular endogenous antioxidant defenses and leads to the acute and long-standing structural and functional changes of macromolecules resulting in impaired cellular functioning, cell death and organ dysfunction. The oxidative stress provoked chain of pathological events over time cause diabetic complications such as nephropathy, peripheral neuropathy, cardiomyopathy, retinopathy, hypertension, and liver disease. Under diabetic conditions, accompanying genome/epigenome and metabolite markers alterations may also affect glucose homeostasis, pancreatic β-cells, muscle, liver, and adipose tissue. By providing deeper genetic/epigenetic insight of direct or indirect dietary effects, nutrigenomics offers a promising opportunity to improve the quality of life of diabetic patients. Natural plant extracts, or their naturally occurring compounds, were shown to be very proficient in the prevention and treatment of different pathologies associated with oxidative stress including diabetes and its complications. Considering that food intake is one of the crucial components in diabetes' prevalence, progression and complications, this review summarizes the effect of the major plant secondary metabolite and phytoconstituents on the antioxidant enzymes activity and gene expression under diabetic conditions.Entities:
Keywords: antioxidant enzymes; diabetes; diabetic complications; nutrigenomics; oxidative stress; phytoconstituents; plant extracts
Year: 2021 PMID: 33803588 PMCID: PMC8003070 DOI: 10.3390/antiox10030480
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Concept of nutrigenomics in diabetes. Nutrients present in food can affect gene expression, cell signaling pathways, and cell metabolism. Those nutrient-gene interactions reflect on epigenome, transcriptome, proteome, and metabolome. Those interactions can be protective and lead to the healthy physiological state or can increase inflammation, oxidation, and metabolic stress which further lead to disturbed glucose homeostasis and progression to diabetes and diabetic complications.
Figure 2Hyperglycemia, oxidative stress, and diabetic complications. Hyperglycaemia and glucose autooxidation are the main sources of free radicals in diabetic condition. Hyperglycaemia contributes to pathogenesis of diabetes, not only by free radical generation, but also through protein glycation and glycosylation, augmented metabolism of glucose through the hexosamine pathway, increased activation of the polyol pathway by unused glucose, glucose-mediated activation of protein kinase C. Under normal circumstances the concentration of ROS is modulated by antioxidant enzymes, antioxidants, and phase II detoxifying enzymes. Those cellular antioxidant defense systems are regulated by a master regulator Nrf-2, as well as by NF-κB. Nrf-2 (nuclear factor erythroid 2-related factor 2), NF-κB (nuclear factor kappa B), ARE (antioxidant response element). Immunohistological images of insulin (brown) present in pancreatic islets are taken from Mihailović et al., “Protective Effects of the Mushroom Lactarius deterrimus Extract on Systemic Oxidative Stress and Pancreatic Islets in Streptozotocin-Induced Diabetic Rats”, Journal of Diabetes Research, ID 576726, 10 pages, 2015. https://doi.org/10.1155/2015/576726 (accessed on 5 March 2021).
Plants with protective effects on pancreas in diabetes pathogenesis.
| Plant Extract | Model | Mechanism of Action | Reference |
|---|---|---|---|
| STZ-induced diabetic rats | Reduces blood glucose level; reduces MDA level; induces GSH level and SOD, CAT, GPx activities; reduces degenerative changes of pancreatic islets. | [ | |
| Methanolic extract | STZ-induced diabetic rats | Improves islet cell content and insulin, GLUT-2, p-Akt levels. | [ |
| Methanolic extract | STZ-treated Rin-5F cells | Increases cell viability, insulin secretion and mRNA level; reduces DNA damage, TBARS, GSSP, CAT and SOD activities; reduces mRNA of CAT, GPx, Mn/CuZnSOD; reduces NFκB-p65 and Nrf-2; induces Akt, ERK, p38, Pdx-1, MafA. | [ |
| Methanolic extract | H2O2/SNP-treated Rin-5F cells | Reduces TBARS, GSSP; increases GSH; modulates activities of CAT, GPx, GR, Mn/CuZnSOD; down-regulates mRNA levels of Mn/CuZnSOD, GPx, CAT. | [ |
| Rat pancreas homogenate | Protection against (AAPH)-induced pancreas damage. | [ | |
| STZ-treated Rin-5F cells | Increases cell viability and insulin protein level; preserves GSH; reduces TBARS, GSSP, DNA damage. | [ | |
| STZ-induced diabetic rats | Cytoprotection. | [ |
Abbreviations: STZ, streptozotocin; SNP, sodium nitroprusside; AAPH, 2,2-azo-bis(2-amidinopropane)dihydrochloride; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione S-transferase; GSSP, glutathione disulfide; MDA, malondialdehyde; TBARS, thiobarbituric acid reactive substances; GSH, glutathione; NF-kB, nuclear factor kappa B; Nrf-2, nuclear factor erythroid 2-related factor 2; GLUT-2, glucose transporter 2; p-Akt, phospho-protein kinase B; ERK, extracellular signal-regulated kinase; p38, mitogen-activated protein kinase; Pdx-1, pancreatic and duodenal homeobox 1; MafA, musculoaponeurotic fibrosarcoma oncogene homolog A; H2O2, hydrogen peroxide; Rin-5F, rat pancreatic cell line.
Protective effects of plant extracts on liver, kidney, and circulation in diabetic condition.
| Plant Extract | Target | Model | Mechanism of Action | Reference |
|---|---|---|---|---|
| Liver/Kidney | STZ- diabetic rats | Improves hyperglycemia and hyperlipidemia; reduces DNA damage and GSSP; improves Mn/CuZnSOD activities; inhibits RAGE/NF-κB pathway. | [ | |
| Ethanolic extract | Liver | STZ- diabetic rats | Induces mRNA levels and the activities of Mn/CuZnSOD and CAT; reduces SOD, CAT and NF-kB glycosilation; increases p-Akt level. | [ |
| Liver | STZ- diabetic rats | Improves activities of SOD, CAT, GPx; cytoprotection. | [ | |
| Kidney | Alloxan-induced diabetic rats | Restores the alterations in FBG and activities of CAT, SOD, GPx. | [ | |
| Kidney | STZ-induced diabetic rats | Increases activity of SOD, CAT, GPx; suppresses total ROS generation and lipid peroxides. | [ | |
| Liver | Alloxan-induced diabetic rats | Increases GSH and activities of CAT and SOD. | [ | |
| Liver | H2O2-treated HepG2 cells | Increases GST activity. | [ | |
| Liver | STZ-diabetic rats | Stimulates GPx, SOD, CAT activity and expression. | [ | |
| Liver | STZ-diabetic rats | Reduces blood glucose, glycosylated hemoglobin, TBARS, hydroperoxides and sorbitol dehydrogenase; increases insulin in plasma and activities of GPx, GST and GSH in the liver. | [ | |
| Liver | STZ- diabetic rats | Increases GSH; decreases MDA; induces GPx and GST activities. | [ | |
| Liver | Alloxan- diabetic rats | Hypoglycemic effect; increases activities and mRNA levels of SOD, GPx and CAT. | [ | |
| Aqueous extract | Circulation | STZ-diabetic rats | Loweres blood glucose levels, total cholesterol, triglycerides and increases HDL. | [ |
| Liver/Kidney | Alloxan-diabetic rats | Improves glucose tolerance and glycemic control and the activities of GPx and SOD. | [ | |
| Liver/ | STZ- | Improves hyperglycemia and hyperlipidemia; reduces DNA damage and TBARS; induces MnSOD, CuZnSOD and CAT activities; reduces glycation of serum proteins and reduces glycosylation of MnSOD, CuZnSOD, CAT. | ||
| Mon./ | APPH-treated RAW 264.7 cells | Induces mRNA and protein levels of SOD1, CAT, GPx1 and HO-1; enhances Nrf-2 pathway. | [ | |
| Red blood cells | STZ- diabetic rats | Induces CuZnSOD, CAT, GR activities; reduces TBARS and GSSP levels; increases GSH; reduces protein glycation and glycosylation; reduces blood glucose and HbA1C. | [ |
Abbreviations: HO-1, heme oxygenase-1; FBG, fasting blood glucose; HDL, high density lipoprotein; α2-M, α2-macroglobulin; IL-4, interleukin-4; IL-10, interleukin-10; RAGE, receptor for advanced glycation end-product; Nrf-2, nuclear factor erythroid 2-related factor 2; Mon./Macro.-like cells, Monocyte-/Macrophage-like cells.
Antidiabetic effects of plant extracts in clinical trials.
| Plant Extract | Target | Model | Mechanism of Action | Reference |
|---|---|---|---|---|
| Circulation Pancreas | T2D patients (oral hypoglycemic therapy) | Reduces FBG, HbA1c and TBARS; elevates TAC, SOD and GSH; improves cell response to insulin and the activity of β-cells. | [ | |
| Circulation | T2D patients (non-insulin treatment) | Loweres HbA1c and MDA in serum and increases insulin sensitivity; increases SOD, GPx and CAT activities and TAC. | [ | |
| Circulation | Diabetic patients with chronic heart disease (oral hypoglycemic therapy) | Increases serum GSH level and activities of SOD, GR and PONase. | [ | |
| Circulation | Healthy human subjects | Reduces oxidative stress and induces SOD and CAT expression in plasma. | [ |
Abbreviations: TAC, total antioxidant capacity; PONase, paraoxonase; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; TBARS, thiobarbituric acid reactive substances; GSH, glutathione; T2D, type 2 diabetes.
Improvement of glucose homeostasis, β-cell viability and function by phytoconstituents.
| Phytoconstituents and Their Sources | Effects | Type of Study | Mechanism of Action | Reference |
|---|---|---|---|---|
| Increases insulin synthesis/secretion and improves glucose tolerance; promotes β-cell survival and proliferation. | INS-1 cells; | Induces Nrf-2-mediated gene expression of GPx, SOD and phase II enzymes and bocks Nf-κB; stimulates PKB/Akt pathway; represses polyol pathway, AGEs production and hyperlipidemia. | [ | |
| Improves β-cell viability and insulin secretion. | STZ-treated INS-1 cells | Reduces lipid peroxidation and improves SOD, CAT, GPx and GST activities. | [ | |
| Improves plasma insulin level; induces proliferation, survival and regeneration of islet and liver cells. | STZ-diabetic mice | Suppresses expression of Cdkn1a and INOS2. | [ | |
| Improves insulin sensitivity; antilipolytic effects in plasma. | HFD diabetic rats | Attenuates TNF-α and free fatty acids levels in plasma. | [ | |
| Antihyperglycemic, antihyperlipidemic effects. | STZ-diabetic rats | Reduces post prandial hyperglycemia and improves dyslipidemia. | [ | |
| Regulates hyperglycemia and dyslipidemia. | T2D patients | Decreases fasting and postload plasma glucose, HbA1c, triglyceride, TC and LDL. | [ |
Abbreviations: Nrf-2, nuclear factor erythroid 2-related factor 2; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; GST, glutathione S-transferase; Nf-κB, nuclear factor kappa B; AGEs, advanced glycation end-products; PKB/Akt, protein kinase B; Cdkn1a, cyclin-dependent kinase inhibitor; INOS2, inducible nitric oxide; TNF-α, tumor necrosis factor-α; LDL, low-density lipoprotein; TC, total cholesterol; HFD, high fat diet; HbA1c, glycated hemoglobin; T2D, type 2 diabetes.
Phytoconstituents—gene interactions in attenuation of diabetic liver and kidney disorders.
| Phytoconstituents and Their Sources | Effects | Type of Study | Mechanism of Action | Reference |
|---|---|---|---|---|
| Reduces TC and increases HDL; liver antioxidant protection. | T2D db/db mice | Lowers TBARS and improves liver SOD, CAT and GPx activities. | [ | |
| Normalizes blood glucose; improves antioxidant protection in liver. | STZ-diabetic rats | Induces hepatic GSH level, SOD, CAT, GPx, GST activities and SOD and GST expression. | [ | |
| Hypoglycemic effect; liver protection. | STZ-NA diabetic mice | Induces hepatic expression of CuZnSOD. | [ | |
| Reduced diabetes-related oxidative stress in liver. | STZ-NA diabetic rats | Lowers blood glucose and HbA1c; increases activities and expression of SOD, CAT, GSH and GPx in the liver. | [ | |
| Renoprotective effect by preventing HG-induced oxidative damage of renal tubular epithelial cells. | HG-treated NRK-52E cells | Increases SOD, GSH, CAT levels; down-regulates activity of GSK-3β and up-regulates activity of Nrf-2; enhances mRNA of NQO-1 and HO-1 genes. | [ | |
| Beneficial effect on kidney function. | STZ-diabetic rats | Normalizes CAT, SOD1 and SOD2 protein levels in kidneys toward control values. | [ | |
| Ameliorates hyperglycemia, dyslipidemia and insulin levels. | STZ-diabetic rats | Promotes Nrf-2 expression and SOD and GPx activities in the liver; increases kidney SOD and GPx activities. | [ | |
| Decreases glycosylation of antioxidant and redox signaling proteins in diabetic liver, kidney and circulation. | STZ- | Improves glucose, triglycerides, HbA1c, AST and ALT in serum; elevates GSH level; induces activities of SOD, CAT and reduces SOD, CAT, HSP70, HSP90 glycosylation in RBCs. | [ | |
| STZ- | Promotes activities of renal MnSOD, CuZnSOD and CAT by inducing their mRNA levels and by reducing their glycosylation. | [ | ||
| STZ- | Restores CAT and Mn/CuZnSOD activities; increases mRNA and protein levels of CuZnSOD and CAT; decreases glycosylation of SOD, CAT, ERK, p38 NFkB-p65, CEBPβ in liver. | [ |
Abbreviations: Nrf-2, nuclear factor erythroid 2-related factor 2; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; GSH, glutathione; GST, glutathione S-transferase; HDL, high density lipoprotein; TC, total cholesterol; HFD, high fat diet; NA, nicotinamide; HO-1, heme oxygenase-1; NQO1, nicotinamide adenine dinucleotide phosphate quinone oxidoreductase 1; HG, high glucose; HbA1c, glycated hemoglobin; HSP70 and HSP90, heat shock proteins 70 and 90; GSK-3β, glycogen synthase kinase-3 beta; RBC, red blood cells; ERK, extracellular signal-regulated kinase; p38, mitogen-activated protein kinase; NFkB-p65, nuclear factor kappa B protein subunit 65; CEBPβ, CCAAT/enhancer-binding protein beta; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NRK-52E cells, rat kidney epithelial cells.
Phytoconstituents attenuate diabetic cardiovascular complications.
| Phytoconstituents and Their Sources | Effects | Type of Study | Mechanism of Action | Reference |
|---|---|---|---|---|
| Attenuated cardiovascular complications. | HFD-induced metabolic syndrome in rats | Increases Nrf-2, HO-1 and decreases NF-kB expression in heart. | [ | |
| Cardioprotection. | HFD-mice model | Activates Nrf-2, HO-1, NQO-1 and inactivates NF-kB. | [ | |
| Inversed relation with ischemic heart disease mortality. | Zutphen Elderly Study of men aged 65–84 years | Reduces the risk of ischemic heart disease. | [ | |
| Improved oxidant-induced endothelial dysfunction and atherosclerosis. | HFD- | Induces NO synthase activity and antioxidant capacity in plasma; increases Nrf-2 and HO-1 expression in aortas; prevents HOCl-induced cellular damage. | [ | |
| Protection of VSMCs from oxidative stress. | VSMCs from Sprague-Dawley rats | Activates Akt/Nrf-2 signaling pathway and up-regulates expression of HO-1. | [ | |
| Atherosclerosis protection. | HUVEC cells | Loweres mRNA and protein expression of VCAM1 and ICAM1 genes. | [ | |
| Cardioprotection. | MI/MIR injured rats; | Lowers MDA and elevates SOD activity in serum; increases protein levels of HO-1, NQO1, Nrf-2; up-regulates Nrf-2, HO-1, NQO1, GCLC, GCLM, Trx1 and GST gene expression. | [ | |
| Cardioprotection. | DOX-induced cardiotoxicity in rats | Elevates mRNA level of myocardial Nrf-2 and SOD. | [ | |
| Inhibition of endothelial inflammation. | Rat aortic endothelial cells | Induces Nrf-2, SOD and HO-1 gene expression. | [ | |
| Reduced myocardial oxidative stress. | DOX-treated BALB/c mice | Increases Nrf-2 and HO-1 myocardial expression. | [ | |
| Cardioprotection. | Ischemic (I/R) rats | Suppresses TNF-α, IL-1β, IL-6 production and induces Nrf-2, GSH, SOD, GPx, HO-1 activity in ischemic myocardium tissue. | [ | |
| Prevents diabetic cardiac oxidative damage and dysfunction. | STZ-induced diabetic mice | Activates cardiac Nrf-2 signaling and mRNA/protein levels of HO-1, NQO1, MT, CAT, SOD1, SOD2. | [ | |
| Attenuates cardiac oxidative stress and complications. | HFD/STZ-T2D rats | Reduces MDA and induces MnSOD activity in heart; | ||
| Protection against myocardial oxidative insult through epigenetic regulation. | H9c2 cell line | Activates Nrf-2 and Sirt2 signaling; induces expression of HO-1, NQO1, GST, GCLM, Keap1 and FOXO3a; decreases expression of miR-140-5p in cardiomyocytes. | [ |
Abbreviations: HFD, high fat diet; ApoE (−/−), apolipoprotein E-deficiency; NO, nitric oxide; HOCl, hypochlorous acid; VSMCs, vascular smooth muscle cells; VCAM1, vascular cell adhesion molecules; ICAM1, intercellular adhesion molecules; HUVEC cells, human umbilical vein endothelial cells;. GCLC, glutamate-cysteine ligase catalytic subunit; GCLM, glutamate-cysteine ligase regulatory subunit; Trx1, thioredoxin-1; HEK293, human embryonic kidney cell line; H9c2, embryonic cardiomyocyte cell line; MI, myocardial infarction; MIR, myocardial ischemia-reperfusion; I/R, ischemia/reperfusion injuries; DOX, doxorubicin; 7-HMR, (−)-7(S)-hydroxymatairesinol; MT, metallothionein; Keap1, kelch-like ECH-associated protein 1; FOXO3a, forkhead box O3; Sirt2, silent information regulators; miR-140-5p, microRNA 140-5p.